<i>Lactococcus cremoris</i> D2022 alleviates hyperuricemia and suppresses renal inflammation <i>via</i> potential gut-kidney axis-Reference-Cited by-同舟云学术

Lactococcus cremoris D2022 alleviates hyperuricemia and suppresses renal inflammation via potential gut-kidney axis

Published:2024 Issue:11 Volume:15 Page:6015-6027
ISSN:2042-6496
Container-title:Food & Function
language:en
Short-container-title:Food Funct.

Author:

Wang Zhihuan¹,Huang Yuanming¹,Yang Tao¹,Song Liqiong¹,Xiao Yuchun¹,Chen Yulu¹,Chen Mengshan¹²,Li Mingding³,Ren Zhihong¹^ORCID

Affiliation:

1. National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Chinese Center of Disease Control and Prevention, Beijing, China

2. School of Medicine, Nankai University, Tianjin, China

3. Maiyata Institute for Beneficial Bacteria, Shaoxing, Zhejiang, China

Abstract

D2022 attenuated HUA via gut-kidney axis.

Funder

National Basic Research Program of China

State Key Laboratory of Infectious Disease Prevention and Control

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/FO/D4FO00118D

Reference41 articles.

1. The gut microbiota as a target to control hyperuricemia pathogenesis: Potential mechanisms and therapeutic strategies

2. D. L.Nelson and M. M.Cox , in Lehninger Principles of Biochemistry , W. H. Freeman and Company , New York, USA , 6th edn, 2013

3. The Role of ABCG2 in the Pathogenesis of Primary Hyperuricemia and Gout—An Update

4. Extra-Renal Elimination of Uric Acid via Intestinal Efflux Transporter BCRP/ABCG2

5. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Increased intestinal permeability and lipopolysaccharide contribute to swainsonine-induced systemic inflammation;Ecotoxicology and Environmental Safety;2024-10